Drug-Drug Interaction Clinical Trial
Official title:
Single-center, Open, Controlled Study to Investigate the Interaction of Metamizole With the Cytochrome p450 System in Healthy Subjects by Application of the Basel Cocktail
Verified date | June 2019 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Investigators conducted a single center, two-phased, open, controlled pharmacokinetic study
to investigate the drug-drug interaction potential of metamizole. For this reason, healthy
male volunteers were screened.
Enrolled participants were phenotyped on day 1 using the Basel Cocktail (phenotyping cocktail
containing specific substrates for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4). After,
they received metamizole treatment for 8 days (3 grams per day). On the 8th day (day 9), they
were phenotyped again with the Basel Cocktail and the respective phenotypes (d1 vs. d9) were
compared.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 31, 2018 |
Est. primary completion date | October 31, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Healthy subjects aged between 18 and 45 years (inclusive) at screening - BMI between 18 and 28 kg/m2 (inclusive) and bodyweight at least 50 kg at screening - systolic blood pressure: 100-140 mmHg, diastolic blood pressure: 60-90 mmHg and heart rate: 45-90 bpm (inclusive), measured on the leading arm, in the supine position at screening - No clinically significant findings on the physical examination at screening - Signed informed consent prior to any study-mandated procedure - Hematology and clinical chemistry results not deviating from the normal range to clinically relevant extent at screening - Ability to communicate well with the investigator to understand and comply with the requirements of the study Exclusion Criteria: - Smoking >5 cigarettes per day - History or clinical evidence of alcoholism or drug abuse within the 3- year period prior to screening - Loss of =250 ml of blood within 3 months prior to screening. Treatment with an investigational drug within 30 days prior to screening - Previous systemic treatment with any prescribed or over the counter medication (including herbal medicines such as St John's Wort) within 2 weeks prior to the intended start of the study - Inability to stop consumption inducing food products (e.g. grapefruit juice) 72 h before start of the study - Excessive caffeine consumption (>8 cups of coffee/ 8l coca cola per day) - Legal incapacity or limited legal capacity at screening - Positive results from urine drug screen at screening - History or clinical evidence of any disease (e.g. gastrointestinal disease: Morbus Crohn, Colitis Ulcerosa, anamnestic gastrointestinal bleeding) and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity - Known hypersensitivity to Metamizole (Novalgin®) or excipients of the drug formulation - Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Clinical Trial Unit, University Hospital Basel | Basel | BS |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect on AUC ratio between parent and metabolite | AUC ratio between parent and metabolite of specific cytochrome P450 substrates to determine a shift which may indicate either induction or inhibition of the specific cytochrome P450 | 12 hours | |
Primary | Cmax | Maximal Concentration in plasma of parent and metabolite | 24 hours | |
Primary | tmax | time to reach Cmax | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05692570 -
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04328766 -
Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03985969 -
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
|
Phase 1 | |
Completed |
NCT03302845 -
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02887443 -
A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate
|
Phase 1 | |
Completed |
NCT01361217 -
The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
|
N/A | |
Completed |
NCT06066060 -
A DDI Study of JMKX000623 and Metformin Hydrochloride
|
Phase 1 | |
Completed |
NCT03723395 -
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
|
Phase 1 | |
Recruiting |
NCT05789173 -
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
|
Early Phase 1 | |
Completed |
NCT04598542 -
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05044962 -
Kuwa Free! - Live Free!
|
N/A | |
Completed |
NCT04487145 -
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
|
Phase 4 | |
Completed |
NCT05108051 -
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
|
Phase 1 | |
Active, not recruiting |
NCT04669678 -
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
|
Phase 4 | |
Completed |
NCT01991327 -
Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
|
Phase 1 | |
Completed |
NCT04218513 -
Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection
|
Phase 1 | |
Completed |
NCT05492318 -
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
|
Phase 1 | |
Completed |
NCT01309854 -
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05339672 -
Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
|
||
Completed |
NCT05306379 -
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
|
Phase 1 |